87
Participants
Start Date
December 1, 2020
Primary Completion Date
December 29, 2021
Study Completion Date
December 29, 2021
Placebo
Placebo will be administered subcutaneously every week for 13 weeks.
leronlimab 700 mg
700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
leronlimab 350 mg
350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
Center for Advanced Research & Education, Gainesville
Meridien Research, Maitland
Floridian Clinical Research, Miami Lakes
Sensible Healthcare, LLC, Ocoee
Care United Research LLC, Forney
American Research Corporation, San Antonio
Southern California Research Center, Coronado
Lead Sponsor
CytoDyn, Inc.
INDUSTRY